Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project (ARON)
Impact of a Diagnostic Algorithm on Antibiotic Prescribing Rate and Further Management of Acutely Ill Children Presenting to Ambulatory Care: Multicentre, Cluster-randomized, Parallel Group Pragmatic Trial
Impact of clinical guidance & point-of-care CRP test in children: the ARON project Trial Design: multicentre, cluster-randomized, parallel group pragmatic trial Trial Participants and setting: Children aged 6 months to 12 years of age with an acute illness episode presenting to in-hours general practice or out-of-hospital community paediatrics offices
Intervention(s) Diagnostic algorithm:
- Clinical decision tree: clinician's gut feeling something is wrong, dyspnea, temperature ≥40ºC
- YES to any : point-of-care CRP ≥5mg/L: additional testing or refer to secondary care <5mg/L: safety netting*, only prescribe antibiotics if advised (guidelines)
NO to all : are AB considered? YES : point-of-care CRP ≥5mg/L: safety netting*, only prescribe antibiotics if advised (guidelines) <5mg/L: safety netting*, do not prescribe antibiotics NO: safety netting
*safety netting advice:
- inform parents on what to expect and what to look out for
- interactive parent information booklet based on previous research
Control: Diagnosis and Treatment/Management as per usual care:
- guidance on AB prescribing:
o Belgische Commissie voor de Coördinatie van het Antibioticabeleid (BAPCOC) guide (updated November 2019)
o RIZIV consensus meeting report "Antibiotics in children in ambulatory care"
Primary Endpoint: Antibiotic prescribing rate at index consultation
Secondary Endpoint(s)
- time until full clinical recovery (during follow up (day 1 to day 30))
- additional investigations (at index consultation and/or during follow up (day 1 to day 30))
- re-consultation (during follow up (day 1 to day 30))
- antibiotic prescribing rate (during follow up (day 1 to day 30))
Exploratory endpoints at the index consultation:
- additional investigations (X-Ray, blood tests, urine tests, etc.)
During a follow-up period (day 1 to day 30):
- referral to hospital
- additional investigations (X-Ray, blood tests, urine tests, etc.)
- patients with full clinical recovery at day 7 and day 30
- admission to hospital
- mortality
- cost-effectiveness
- patient satisfaction
- qualitative study: endpoints
Planned Sample Size: 7000 Timing of the intervention: Intervention at index consultation (at presentation to primary care) Follow-up duration: 30 days follow-up Duration of the trial (FPI-CSR): 43 months
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The investigators aim to strengthen the assessment of acutely ill children in primary care, by introducing a diagnostic algorithm that can decrease antibiotic prescribing.
In light of the prior evidence and its results so far, the ARON trial will test the impact of a diagnostic algorithm including a standardised clinical assessment, a POC CRP test, and safety netting advice.
Therefore, the investigators propose to assess the clinical and cost-effectiveness of a diagnostic algorithm which includes a decision tree, POC CRP and safety netting advice in acutely ill children aged 6 months to 12 years of age presenting to ambulatory care, on AB prescribing, referral/admission to hospital, additional testing, mortality, and patient satisfaction.
More specifically, the investigators' research question is whether this diagnostic algorithm is able to safely reduce antibiotic prescribing in acutely ill children presenting to ambulatory care.
The decision whether or not to conduct a POC CRP test will depend on the standardized clinical assessment, i.e. a validated clinical decision tree, and subsequently for low-risk children on the intention to prescribe AB.
The investigators will provide clear evidence-based guidance on how to interpret the CRP test result as outlined below.
A process evaluation will examine how clinicians use CRP testing in their practice and how parents experience these consultations.
The investigators propose a study, where children (6 months to 12 years of age) will be randomised to (a) a diagnostic algorithm with CRP testing and specific guidance on when to prescribe AB or (b) usual care. CRP testing will be done using a finger prick test (result within 4 minutes). The CRP level will then be given to the clinician who will communicate the result to the child/parents.
The investigators aim to recruit 7000 children and will collect data registered by the participating physician, from the child's health record and children/parents directly. The investigators will describe how the intervention has worked in practice and how clinicians/parents have experienced these consultations.
Guidance will be part of a diagnostic algorithm which includes clinically guided POC CRP testing and safety netting advice to inform parents on what to expect and what to look out for.
Individual interviews will be conducted with clinicians and parents taking part in the trial within 30 days after the first contact consultation, to explore the social processes influencing embedding of the intervention within practice, and behaviour change techniques.
These individual telephone interviews will be performed with a selection of parents to address whether their concerns were discussed appropriately and whether their expectations were met and how they experienced the consultation and/or POC CRP testing.
The safety-netting advice will be supported by a parent information booklet, based on previous research (the "When should I worry"-interactive booklet (a guide to Coughs, Colds, Earache & Sore Throats), the "Mijn kind heeft koorts" booklet (Eefje de Bont, www.thuisarts.nl), and the "Caring for children with coughs"-leaflet (information about how to look after a child who has a cough and when to see the doctor)).
The findings of this study could change the practice of ambulatory care physicians and might be of great interest to parents and childcare providers. The investigators will publish the findings of this research in academic journals, present at national conferences and discuss results with groups responsible for the national guidance on how to assess acutely ill children (Domus Medica, SSMG).
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Tine De Burghgraeve, PhD
- Phone Number: +3216 37 76 72
- Email: tine.deburghgraeve@kuleuven.be
Study Locations
-
-
-
Leuven, Belgium, 3000
- GPs associated with KU Leuven
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria for practices:
- Being able to recruit acutely ill children (ideally consecutively)
- Agree to the terms of the clinical study agreement.
Exclusion Criteria for practices:
- Currently using a POC CRP device as part of their routine care
- No practices will be excluded on other grounds than the above. Age, demographics, geographic region will not be used to exclude eligible practices. This will provide us with a real-life, representative subset of ambulatory care physicians.
Inclusion criteria for children
- Children aged 6 months to 12 years, provided informed consent can be obtained
- presenting with an acute illness episode that started maximum 10 days before the index consultation
Exclusion criteria for children
- Children who were previously included in this trial
- children with an underlying known chronic condition (e.g. asthma, immune deficiency)
- clinically unstable warranting immediate care
- immunosuppressant medication taken in the previous 30 days
- trauma as the main presenting problem
- antibiotics taken in the previous 7 days
- Unwillingness or inability to provide informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Intervention: Diagnostic algorithm
diagnostic algorithm including a standardised clinical assessment, a Point-of-care C-reactive protein test, and safety netting advice
|
Guidance will be part of a diagnostic algorithm which includes clinically guided point-of-care C-reactive protein testing and safety netting advice to inform parents on what to expect and what to look out for. A selection of clinical features will be assessed and recorded by the physician in the patient's health record and on the e-CRF, including the clinical decision tree (clinician's gut feeling, body temperature, dyspnea). The safety-netting advice will be supported by a parent information booklet, based on previous research (the "When should I worry"-interactive booklet (a guide to Coughs, Colds, Earache & Sore Throats), the "Mijn kind heeft koorts" booklet (Eefje de Bont, www.thuisarts.nl), and the "Caring for children with coughs"-leaflet (information about how to look after a child who has a cough and when to see the doctor)). |
|
No Intervention: Usual care
In the control arm, patients will receive 'usual care' left at the discretion of the treating physician. Apart from the general training session for all participating physicians they have attended prior to recruitment and randomization, physicians in the control arm will not receive additional tools. They are expected (but not forced) to follow the Belgian guidelines (as described in "BAPCOC National guidelines and the RIZIV consensus meeting "Rational use of antibiotics in children"). |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Antibiotic Prescribing Rate at Index Consultation (Immediate or Delayed)
Time Frame: This outcome will be registered immediately at the index consultation (immediately after the intervention)
|
The primary outcome is the percentage of participants who were prescribed antibiotic treatment (both immediate and delayed) at the index consultation as recorded by the treating physician.
|
This outcome will be registered immediately at the index consultation (immediately after the intervention)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Recovery During Follow-up
Time Frame: This outcome will be checked from the diary (via app for parents) from first day after the intervention until day of full clinical recovery (up to maximum 30 days after after the intervention)
|
the duration (in days) until reaching full clinical recovery
|
This outcome will be checked from the diary (via app for parents) from first day after the intervention until day of full clinical recovery (up to maximum 30 days after after the intervention)
|
|
Additional Investigations at Index Consultation and/or During Follow-up
Time Frame: This composite outcome will be registered immediately after the intervention and/or checked from the patient health record from the first day to day 30 after the intervention
|
the percentage of subjects receiving additional testing (including, but not limited to (X-Ray, blood tests, urine tests) at index consultation (day 0) and/or during follow-up (day 1 to day 30)
|
This composite outcome will be registered immediately after the intervention and/or checked from the patient health record from the first day to day 30 after the intervention
|
|
Re-consultation During Follow-up
Time Frame: This outcome will be checked from the patient health record from first day to day 30 after the intervention
|
percentage of subjects who re-consulted their physician during follow-up (day 1 to day 30)
|
This outcome will be checked from the patient health record from first day to day 30 after the intervention
|
|
Antibiotic Prescribing Rate During Follow-up
Time Frame: This outcome will be checked from the patient health record first day to day 30 after the intervention
|
percentage of subjects who were prescribed antibiotic treatment during follow-up (day 1 to day 30)
|
This outcome will be checked from the patient health record first day to day 30 after the intervention
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Additional Testing at Index Consultation
Time Frame: This outcome will be registered immediately at the index consultation
|
percentage of subjects receiving additional testing (including, but not limited to (X-Ray, blood tests, urine tests) at index consultation (day 0)
|
This outcome will be registered immediately at the index consultation
|
|
Additional Testing During Follow-up
Time Frame: during follow-up from first day to day 30 after the intervention
|
percentage of subjects receiving additional testing (including, but not limited to (X-Ray, blood tests, urine tests) during follow-up (day 1 to day 30)
|
during follow-up from first day to day 30 after the intervention
|
|
Referral to Hospital at Day 0
Time Frame: This outcome will be registered immediately at the index consultation
|
percentage of subjects referred to hospital at index consultation (day 0)
|
This outcome will be registered immediately at the index consultation
|
|
Referral to Hospital During Follow-up
Time Frame: during follow-up from first day to day 30 after the intervention
|
percentage of subjects referred to hospital during follow-up (day 1 to day 30)
|
during follow-up from first day to day 30 after the intervention
|
|
Admission to Hospital at Day 0
Time Frame: This outcome will be registered immediately at the index consultation
|
percentage of subjects admitted to hospital at index consultation (day 0)
|
This outcome will be registered immediately at the index consultation
|
|
Admission to Hospital During Follow-up
Time Frame: during follow-up from first day to day 30 after the intervention
|
percentage of subjects admitted to hospital during follow-up (day 1 to day 30)
|
during follow-up from first day to day 30 after the intervention
|
|
Mortality at Day 0
Time Frame: This outcome will be registered immediately at the index consultation
|
percentage of subjects who died at index consultation (day 0)
|
This outcome will be registered immediately at the index consultation
|
|
Mortality During Follow up
Time Frame: during follow-up from first day to day 30 after the intervention
|
percentage of subjects who died during follow-up (day 1 to day 30)
|
during follow-up from first day to day 30 after the intervention
|
|
Clinical Recovery at Day 7
Time Frame: at day 7 after the intervention
|
percentage of subjects with full clinical recovery at day 7
|
at day 7 after the intervention
|
|
Clinical Recovery at Day 30
Time Frame: at day 30 after the intervention
|
percentage of subjects with full clinical recovery at day 30
|
at day 30 after the intervention
|
|
Patient's Experience Through Semi-structured Interviews
Time Frame: within 7 days after the intervention
|
Patient's experience through semi-structured interviews with pre-defined topic guide
|
within 7 days after the intervention
|
|
Parent's Experience Through Semi-structured Interviews
Time Frame: within 7 days after the intervention
|
Parent's experience through semi-structured interviews with pre-defined topic guide
|
within 7 days after the intervention
|
|
Physician's Experience Through Semi-structured Interviews
Time Frame: within 7 days after the intervention
|
Physician's experience through semi-structured interviews with pre-defined topic guide
|
within 7 days after the intervention
|
|
Cost-effectiveness of the Intervention
Time Frame: will be assessed retrospectively after data collection has finished (24 months of recruitment)
|
Cost-effectiveness of the intervention: healthcare expenditures in terms of hospitalization, consultations, pharmaceuticals (reimbursed and non-reimbursed), productivity, quality of life
|
will be assessed retrospectively after data collection has finished (24 months of recruitment)
|
|
Number of Participants Whose Physician Was Non-Adherent to the Diagnostic Algorithm
Time Frame: This outcome will be registered immediately at the index consultation
|
clinicians could deviate from the proposed diagnostic algorithm.
This outcome measure comprise the percentage of participants whose physician was non-adherent to the diagnostic algorithm.
This is not a protocol violation, since deviating from the algorithm was a possibility if the physician deems this necessary.
|
This outcome will be registered immediately at the index consultation
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jan Y Verbakel, MD, PhD, KU Leuven
Publications and helpful links
General Publications
- Verbakel JY, Lemiengre MB, De Burghgraeve T, De Sutter A, Aertgeerts B, Bullens DMA, Shinkins B, Van den Bruel A, Buntinx F. Point-of-care C reactive protein to identify serious infection in acutely ill children presenting to hospital: prospective cohort study. Arch Dis Child. 2018 May;103(5):420-426. doi: 10.1136/archdischild-2016-312384. Epub 2017 Dec 21.
- Verbakel JY, Aertgeerts B, Lemiengre M, Sutter AD, Bullens DM, Buntinx F. Analytical accuracy and user-friendliness of the Afinion point-of-care CRP test. J Clin Pathol. 2014 Jan;67(1):83-6. doi: 10.1136/jclinpath-2013-201654. Epub 2013 Sep 11. No abstract available.
- Verbakel JYJ, De Burghgraeve T, Van den Bruel A, Coenen S, Anthierens S, Joly L, Laenen A, Luyten J, De Sutter A. Antibiotic prescribing rate after optimal near-patient C-reactive protein testing in acutely ill children presenting to ambulatory care (ARON project): protocol for a cluster-randomized pragmatic trial. BMJ Open. 2022 Jan 3;12(1):e058912. doi: 10.1136/bmjopen-2021-058912.
- Verbakel JY, Lemiengre MB, De Burghgraeve T, De Sutter A, Aertgeerts B, Shinkins B, Perera R, Mant D, Van den Bruel A, Buntinx F. Should all acutely ill children in primary care be tested with point-of-care CRP: a cluster randomised trial. BMC Med. 2016 Oct 6;14(1):131. doi: 10.1186/s12916-016-0679-2. Erratum In: BMC Med. 2017 May 2;15(1):93. doi: 10.1186/s12916-017-0861-1.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- S62005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infection
-
NCT05977868TerminatedSkin and Soft Tissue Infection | Gastrointestinal Infection | Pulmonary Infection | Bone and Joint Infection | Endovascular Infection | Genitourinary Infection
-
NCT06402591Active, not recruitingSurgical Site Infection | Joint Infection | Infection, Surgical Site | Infection Prosthesis Hip and Knee | Infection, Prosthesis Related | Infection Pro
-
NCT05797818CompletedSurgical Site Infection | Nosocomial Infection | Healthcare Associated Infection
-
NCT00975377CompletedSurgical Site Infection | Superficial Surgical Site Infection | Deep Surgical Site Infection | Organ/Space Surgical Site Infection
-
NCT03284749CompletedSurgical Site Infection | Wound Infection | Cesarean Section; Infection | Perineal Infection
-
NCT05021315RecruitingPostoperative Infection | Cesarean Section Complications | Vaginal Infection
-
NCT06172010RecruitingProsthetic-joint Infection | Infection Hip | Infection; Knee, Joint
-
NCT04618276CompletedProsthetic Joint Infection | Surgical Site Infection | Prosthesis and Implants | Postoperative Wound Infection Deep Incisional Surgical Site
-
NCT04067843CompletedProsthetic Joint Infection | Surgical Site Infection | Prosthesis and Implants | Postoperative Wound Infection Deep Incisional Surgical Site
-
NCT04488458RecruitingProsthetic Joint Infection | Hip Prosthesis Infection | Prosthetic Infection | Knee Prosthesis Infection
Clinical Trials on diagnostic algorithm
-
NCT04459169UnknownCardiac Amyloidosis
-
NCT02404948CompletedCoronary Artery Disease
-
NCT06204926RecruitingIntraoperative Complications | Postoperative Outcomes | Small-incision Lenticule Extraction (SMILE) Surgery | Deep Convolutional Neural Network
-
NCT06669728RecruitingMyopia | Posterior Chamber Phakic Intraocular Lens | Vault | Deep Neural Network | Anterior Chamber Angle
-
NCT03759483CompletedDiagnositic Efficacy of Deep Convolutional Neural Network in Differentiation of Glaucoma Visual Field From Non-glaucoma Visual Field
-
NCT05176015CompletedStroke, Acute | Nystagmus, Acquired
-
NCT02358603Terminated
-
NCT06324136Recruiting
-
NCT07067528Not yet recruitingPost-Tuberculous Bronchiectasis | Post Pulmonary Tuberculosis
-
NCT01324037CompletedSuspected Upper Extremity Deep Vein Thrombosis